Monebo works together with pharmaceutical companies, clinicians, regulatory agencies and academic institutions to deliver better and more efficient ways to assess drug safety

Austin, TX, February 15, 2010, PRWeb:

Monebo Technologies, a leader in the monitoring and interpretation of the electrical activity of the heart, today announced it has become a member of the Cardiac Safety Research Consortium (CSRC). As a member, Monebo will work with the group to better understand the issues surrounding the impact drugs have on the heart, and develop methods and tools for quickly and accurately assessing the safety of a particular pharmaceutical compound.

The CSRC was founded in 2006 with a mission to advance the scientific knowledge on cardiac safety for new and existing medical products by building a collaborative environment. It is based upon the principles of the FDA’s Critical Path Initiative, which aims to stimulate and facilitate a national effort to modernize the scientific process through which a potential human drug, biological product, or medical device is transformed from a discovery or “proof of concept” into a medical product. CSRC is comprised of thought leaders from the U.S. Food and Drug Administration, pharmaceutical companies, clinicians, and companies supplying technology, tools, or expertise in the area of cardiac safety.

Monebo has extensive experience in ECG technology and has developed tools for fully automated analysis, which should lead to more efficient, accurate and reproducible pharmaceutical cardiac safety studies. Additionally, Monebo is working to validate the use of new biomarkers that would signal an impending issue that could lead to an arrhythmia. Working with the CSRC, Monebo intends to further investigate these technologies, and also provide expertise on other research projects undertaken by the CSRC and its members.

“We are extremely pleased to become a member of the CSRC,” said Dale Misczynski, President and CEO of Monebo. “We fully support its mission as it coincides with our own in advancing the science of the drug development process. Working with the group, we intend to contribute technology, expertise and a willingness to explore new and better ways to balance the benefits of new drugs with any potential risk.”

“We welcome Monebo to the CSRC,” stated Mitchell W. Krucoff, MD, Professor of Cardiovascular Medicine at Duke University and CSRC co-chair. “Monebo has been committed to developing technology consistent with our mission and their addition strengthens the group. We look forward to utilizing their unique talents as we continue to advance the understanding and application of technology as it is applied to cardiac safety.”